Tretinoin

Also known as: ATRA Retinoic Acid All-trans retinoic acid

Active ingredient description

Tretinoin decreases cohesiveness of follicular epithelial cells resulting in decreased microcomedone formation. Additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells, causing extrusion of the comedones.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Tretinoin
D Dermatologicals → D10 Anti-acne preparations → D10A Anti-acne preparations for topical use → D10AD Retinoids for topical use in acne
Discover more medicines within D10AD01
Tretinoin
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XF Retinoids for cancer treatment
Discover more medicines within L01XF01

Medicines

Tretinoin is the active ingredient of these drugs:

Drug
Countries

Hong Kong

Hong Kong

Estonia South Africa

United States

United States

United States

Finland

Ecuador

Estonia

Germany

South Africa

France

South Africa

Estonia France Hong Kong

Tunisia

Spain

United States

United States

France Singapore South Africa

South Africa

Canada Estonia United States

Estonia Spain

New Zealand Singapore

Canada Singapore

Austria Brazil Canada Estonia Finland

Brazil Hong Kong

Brazil

Tretinoin is also found within below combination drugs:

ACNATAC , ACTIN-NEO , AKNEMYCIN PLUS , ATREDERM , BALISA VAS , BETARRETIN H , BIACNA , EFASOL , ERYLIK , HORMOSKIN , OSKIN , SUAVICID , TRECLIN , TRECLINAC , TRI-LUMA , TRINULOX , UREOTOP AND VAS , VELTIN , VITACID ACNE , VITACID PLUS , ZANEA , ZIANA

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
UK
Structured Product Labeling (SPL)
US

Structural formula

Graphic representation of the active ingredient's molecular structure

Molecular mass: 300.442 g/mol

External identifiers

CAS Substance: 302-79-4
DrugBank Drug: DB00755
KEGG Drug: D00094
RxNorm Ingredient: 10753
SNOMED-CT Concept: 387305002
Tretinoin (substance)
UNII Identifier: 5688UTC01R
TRETINOIN